The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C09 | Agents acting on the renin-angiotensin system | |
| 3 | C09D | Angiotensin II antagonists, combinations | |
| 4 | C09DB | Angiotensin II antagonists and calcium channel blockers | |
| 5 | C09DB05 | Irbesartan and amlodipine |
| Active Ingredient | Description | |
|---|---|---|
| Irbesartan and Amlodipine |
The pharmacodynamic properties of each drug, irbesartan and amlodipine, provide an additive antihypertensive effect when administered in combination compared to the effect of each drug administered separately. Irbesartan is a specific angiotensin II receptor antagonist (AT1 subtype) and amlodipine is a dihydropyridine calcium antagonist. Both AT1 receptor antagonists and calcium channel blockers lower blood pressure by reducing peripheral resistance, but calcium influx blockade and reduction of angiotensin II vasoconstriction are complementary mechanisms. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| APROVASC Film-coated tablet | Marketing Authorisation Holder | MPI, Generic |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
